IRIS
BOCCHIA, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.907
EU - Europa 13.556
AS - Asia 2.159
SA - Sud America 35
AF - Africa 24
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 12
Totale 31.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.872
GB - Regno Unito 4.124
IE - Irlanda 2.661
IT - Italia 1.796
CN - Cina 1.587
UA - Ucraina 1.374
SE - Svezia 1.183
FR - Francia 765
DE - Germania 571
RU - Federazione Russa 449
FI - Finlandia 383
SG - Singapore 241
VN - Vietnam 123
TR - Turchia 63
BE - Belgio 50
IN - India 41
CZ - Repubblica Ceca 39
NL - Olanda 32
CA - Canada 28
ES - Italia 21
JP - Giappone 21
IR - Iran 20
AU - Australia 19
HK - Hong Kong 19
EE - Estonia 17
PL - Polonia 17
EG - Egitto 16
BR - Brasile 12
CL - Cile 9
EU - Europa 9
GR - Grecia 9
CH - Svizzera 8
AR - Argentina 7
DK - Danimarca 7
RO - Romania 7
LU - Lussemburgo 6
PH - Filippine 6
PT - Portogallo 6
AT - Austria 5
MA - Marocco 5
MX - Messico 5
RS - Serbia 5
AZ - Azerbaigian 4
ID - Indonesia 4
NZ - Nuova Zelanda 4
SA - Arabia Saudita 4
BG - Bulgaria 3
EC - Ecuador 3
HR - Croazia 3
LA - Repubblica Popolare Democratica del Laos 3
MY - Malesia 3
NG - Nigeria 3
PK - Pakistan 3
TH - Thailandia 3
BO - Bolivia 2
CW - ???statistics.table.value.countryCode.CW??? 2
IL - Israele 2
IM - Isola di Man 2
KR - Corea 2
KZ - Kazakistan 2
LT - Lituania 2
LV - Lettonia 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
SM - San Marino 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BD - Bangladesh 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
PA - Panama 1
UZ - Uzbekistan 1
Totale 31.716
Salva come PNG Salva come JPEG
Città #
Southend 3.821
Dublin 2.646
Fairfield 2.487
Ashburn 1.510
Chandler 1.353
Houston 1.245
Woodbridge 1.239
Jacksonville 1.112
Wilmington 1.001
Seattle 954
Cambridge 789
Ann Arbor 648
Princeton 523
Siena 493
Nanjing 399
Beijing 321
Boardman 203
San Mateo 179
Helsinki 160
Singapore 159
San Diego 130
Dearborn 125
Florence 124
Dong Ket 122
Nanchang 117
Moscow 105
New York 105
Milan 91
Hebei 82
Shanghai 82
Shenyang 74
Tianjin 69
Rome 65
London 58
Kunming 54
Menlo Park 53
Jiaxing 52
Izmir 50
Brussels 48
Jinan 44
Changsha 40
Falls Church 40
Norwalk 40
Brno 33
Düsseldorf 31
Washington 31
Guangzhou 26
Hangzhou 26
Ningbo 26
San Francisco 26
Turin 23
Fremont 21
Zhengzhou 21
Kilburn 20
Hefei 19
Lanzhou 19
Lappeenranta 18
Bologna 17
Taizhou 17
Tallinn 17
Amsterdam 16
Dallas 16
Toronto 15
Edinburgh 14
Changchun 13
Munich 13
Redwood City 13
Chiswick 12
Málaga 12
Venezia 12
Atlanta 11
Haikou 11
Hong Kong 11
Hounslow 11
Leawood 11
Livorno 11
Palermo 11
New Bedfont 10
Padova 10
Poggibonsi 10
Cairo 9
Colle Di Val D'elsa 9
Frankfurt am Main 9
Monza 9
Phoenix 9
Pisa 9
Sutri 9
Tokyo 9
Bari 8
Canberra 8
Chicago 8
Los Angeles 8
Philadelphia 8
Prato 8
Sacramento 8
Salerno 8
Stockholm 8
Tappahannock 8
The Dalles 8
Zanjan 8
Totale 23.814
Salva come PNG Salva come JPEG
Nome #
null 398
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 367
Mycosis Fungoides: a therapeutical review 320
MACOP-B versus F-MACHOP regimen in the treatment of high grade Non-Hodgkin’s Lymphomas 293
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 214
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 212
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 202
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 196
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 194
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 191
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 190
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 190
Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome 189
Second generation proteasome inhibitors in multiple myeloma 187
New perspectives for patients with primary CNS lymphoma 171
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 170
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 168
Central nervous system multiple myeloma 160
Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis 158
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma 157
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 157
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 156
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 155
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 155
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party 154
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 154
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 153
Unravelling the response of chronic lymphocytic leukemia to a novel class of anticancer agents, the pyrrolonaphthoxazepines (PNOXs) 153
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 151
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 150
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 150
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 150
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses 149
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 149
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 149
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma 147
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 146
Evolving treatments in multiple myeloma patients with renal failure 144
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 144
Emerging drugs in chronic myelogenous leukaemia 144
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 143
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma 143
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 142
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 142
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 142
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 141
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice 141
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML working party analysis 140
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 139
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 138
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 138
Prognostic role of m2 Tumour-Associated macrophages in lymphoproliferative disorders 138
Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib 138
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 138
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party 137
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 137
Primary Nasopharyngeal Hodgkin Lymphoma 137
Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review 136
Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma 134
Peptide vaccines for hematological malignancies: a missed promise? 133
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 133
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia 132
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 132
Treatment of smoldering multiple myeloma 131
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 131
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 131
null 130
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 130
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: The GIMEMA working party on CML 130
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 129
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia 129
Differences among young adults, adults and elderly chronic myeloid leukemia patients 129
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 129
Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases 128
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party 128
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 128
Primary CNS lymphoma: latest updates and a 10-year monocenter experience 128
Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma 128
Unusual localizations of plasmacytoma 128
Hyperlipidemia in a myeloma patient after bortezomib treatment 127
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 127
The response to imatinib and interferon- is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 127
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 126
Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes. 126
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 126
Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas 126
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 126
Alpha-2b recombinant interferon (Intron) in Hodgkins' lymphoma: Therapeutic perspective 124
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 124
Extramedullary myeloma relapses 123
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up 123
Central Nervous System Multiple Myeloma 121
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma 121
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 121
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline 121
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report 120
FLT3 inhibitors in the management of acute myeloid leukemia 120
Fludarabine: An active agent in the treatment of previously treated and untreated low grade non-Hodgkin's lymphoma 119
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up 119
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 119
Totale 15.164
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.153
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.053 0 201 477 1.114 463 554 587 905 593 586 165 408
2020/20215.411 242 628 274 570 307 572 300 785 483 410 397 443
2021/20223.671 264 441 256 332 154 154 137 140 202 404 419 768
2022/20235.251 333 348 634 714 510 1.032 129 476 534 69 343 129
2023/20244.645 182 119 368 336 175 1.035 1.407 397 62 127 87 350
2024/2025702 334 368 0 0 0 0 0 0 0 0 0 0
Totale 32.434